RxDoctor Payments Data

Angela Young Achong Mejia, MD

Neurology · Dallas, TXNPI 1306898085

Payments from drug & device makers

$402,610in general payments, 2019–2025

Across 235 payments — averaging $1713.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$301K
  • Eisai Inc.$100K
  • Novartis$208
  • Pfizer$184
  • Genentech USA, Inc.$163
  • Hospira, Inc.$72
  • plus $414 from 14 others

What the payments were for

  • Food & beverage$2,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$402,610 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$200,497
Medicare patients
226
Services billed
20,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4613$267,054
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$37,312
TrileptalOxcarbazepine12$22,526
UbrelvyUbrogepant17$15,356
LyricaPregabalin11$15,233
QuliptaAtogepant14$14,728
Emgality PenGalcanezumab-Gnlm14$8,213
Memantine Hcl ErMemantine Hcl81$7,071
Levetiracetam42$4,083
Gabapentin129$2,977
RivastigmineRivastigmine Tartrate25$2,671
Donepezil Hcl94$2,183
Pyridostigmine Bromide31$2,100
Memantine Hcl49$1,980
Mycophenolate Mofetil16$1,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$17$37,31215 claims
AbbVieUbrelvy, Qulipta$301,472$30,08331 claims
PfizerLyrica$184$15,23311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →